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The C57BL/6 mouse strain serves as the genetic background
of many transgenic and gene knockout models; however,
this strain appears to be resistant to hypertension-induced
renal injury. We developed a new model of hypertensive
end-organ damage in C57BL/6 mice by combining
deoxycorticosterone acetate (DOCA) and salt with
angiotensin II infusion. The systolic blood pressure (SBP)
was significantly elevated in DOCA salt–angiotensin II mice
compared to control mice or mice treated individually
with DOCA salt or angiotensin II. Hypertensive glomerular
damage, increased expression of profibrotic and
inflammatory genes, albuminuria, tubular casts, increased
plasma cholesterol, cardiac hypertrophy, and fibrosis were
found in mice treated with DOCA salt–angiotensin II. The SBP
in the angiotensin II-infused group was further increased
by increasing the infusion rate; only mild injury was observed
in these mice, suggesting that blood pressure was not a
causal factor. Removal of DOCA and the angiotensin pump
lowered blood pressure to normal; however, albuminuria
along with the glomerular and cardiac damage did not
completely resolve. Our study describes a new model of
hypertensive end-organ damage and repair in C57BL/6 mice.
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Mice with targeted disruption of genes implicated in the
development and progression of hypertension are valuable
tools for the study of mechanisms leading to organ injury. The
kidney is a target organ for hypertensive end-organ damage
characterized by proteinuria, inflammation, and fibrosis.
Arterial hypertension leads to profound renal damage in rats
but not in all mice strains. Especially, C57BL/6 mice appear to
be very resistant to hypertensive end-organ damage.1 In
addition, C57BL/6 mice appear also to be very resistant
against models of renal injury like angiotensin II (Ang II)
infusion, protein overflow, or renal ablation.2–4 Thus, it is
difficult to study renal disease in genetically modified mice
because the C57BL/6 strain serves as a background for many
transgenic and knockout mouse models.
Therefore, we sought to develop a new model of arterial
hypertension in C57BL/6 mice by combining deoxycorticos-
terone acetate (DOCA) salt and chronic Ang II infusion. This
model shows hypertensive renal injury with proteinuria in
the nephrotic range, cardiac hypertrophy, and fibrosis within
3 weeks after induction of hypertension.
RESULTS
Histology
Hypertensive focal and segmental injury was found in the
glomeruli of DOCAþAng II mice (Figure 1a). Quantitative
analysis of the glomerular injury by scoring is shown in
Figure 1b.
Renal gene expression
Reverse transcriptase (RT)-PCR analyses of mRNA showed
increased expression of collagen, fibronectin, and protein
plasminogen activator inhibitor-1 as well as the chemokines
monocyte chemotactic protein-1 and interferon-inducible
protein-10 in the DOCAþAng II mice (Figure 2a and b).
Albuminuria
Heavy proteinuria (191±39 mg albumin per mg creatinine)
was found in the DOCAþAng II mice at the end of the
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experiment (Figure 3a). Proteinuria occurred early in the
DOCAþAng II mice since protein excretion averaged
already 154±42 4 days after start of the Ang II infusion. In
addition, proteinuria in the DOCAþAng II mice was in the
nephrotic range since plasma cholesterol in this group was
significantly elevated (Figure 3b). As a morphologic correlate
of proteinuria, periodic acid Schiff (PAS)-stained kidney
sections revealed proteinaceous casts in the DOCþAng II
group (Figure 3c). Quantification is shown in Figure 3d.
Body weight, blood pressure, and renal function
Increased systolic blood pressure (SBP) was measured in the
DOCA and the Ang II mice. The means of the four last blood
pressure measurements are shown in Table 1. DOCAþAng II
mice had the highest blood pressure. A time course of the
SBP is shown in Figure 4. Plasma creatinine was slightly but
not significantly decreased in the DOCA and DOCAþAng II
mice, whereas it was significantly increased in the Ang II-
treated mice. Blood urea nitrogen was significantly decreased
in the DOCA mice suggesting hyperfiltration, which is
known in hyperaldosteronism5 (Table 1).
Cardiac changes
An increased heart weight was found in the DOCAþAng II
mice (Figure 5a). Histological examination revealed interstitial
and perivascular fibrosis in the DOCAþAng II mice.
These changes were occasionally found in the Ang II mice
(Figure 5b). Quantification of the cardiac changes is shown in
Figure 5c. Cardiac hypertrophy is often associated with altered
expression of fetal encoded genes in the heart.6 RT-PCR
revealed increased expression of atrial natriuretic protein, brain
natriuretic protein, the ratio of myosin heavy-chain isoforms,
and fibronectin in the DOCAþAng II mice (Figure 6).
Blood pressure
DOCAþAng II mice had significantly higher SBP than
controls, DOCA, and Ang II mice (Table 1). To examine
whether the increased renal injury observed in the DOC-
AþAng II mice was simply due to the higher blood pressure, a
dose–response curve with increasing Ang II concentration was
performed (n¼ 3 in each group). SBP increased to 129±5
and 153±4 mm Hg with 2 and 4 ng g1 min1 Ang II. How-
ever, only mild albuminuria and glomerular damage were
observed (albuminuria: 1.3±0.7 and 3.0±2.0 albumin/creati-
nine, glomerular injury score: 0.033±0.00 and 0.056±0.01).
Angiotensin II receptors
No upregulation of the renal angiotensin type 1a (AT 1a)
receptor (DOCA 0.43±0.18-fold, Ang II 0.54±0.06-fold,
and DOCAþAng II 0.47±0.18-fold vs controls) or AT-2
receptor mRNA expression (DOCA 0.56±0.0.03-fold, Ang II
0.91±0.12-fold, and DOCAþAng II 1.25±0.35-fold vs
controls) could be detected in the hypertensive groups.
Electron microscopy
Electron microscopy confirmed the glomerular injury in the
DOCAþAng II mice, but no ultrastructural evidence of
podocyte or basal membrane damage was found (Figure 7).
Glomerular size
Glomerular size was significantly increased in DOCA and
DOCAþAng II mice compared to controls as shown in
Figure 8.
Resolution
SBP decreased within 2 days after removal of the pellet and
the pump to 93±2 mm Hg. As shown in Figure 9a, albumin-
uria declined but did not normalize within 28 days. The
glomerular sclerosis score averaged 0.27±0.07, which was
below the score of 0.38±0.07 in the DOCAþAng II group.
However, this difference was not statistically significant. Typical
changes of the glomerular morphology with matrix expansion
and segmental sclerosis are shown in Figure 9b. Glomerular
hypertrophy persisted (0.28 106±0.01 106mm3). Expres-
sion of the matrix components, profibrotic markers, and
chemokines was attenuated, but did not normalize. The
decrease was only significant for plasminogen activator
inhibitor-1 (6.0±1.0 vs 16.1±2.0, Po0.05) and collagen 1
Controls
DOCA+Ang II
DOCA
Ang II
Glomerular injury score
0
0.1
0.2
0.3
0.4
0.5
Controls DOCA Ang II DOCA+Ang II
G
lo
m
er
ul
ar
 in
jur
y (
sc
ore
)
*
Figure 1 | Renal injury. Representative examples of glomerular
morphology (PAS, original magnification  630, under oil
immersion). (a) Severe glomerular injury was found in the
DOCAþAng II mice. (b) Semiquantitative analysis of glomerular
injury by scoring. *Po0.001 vs all other groups.
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(1.6±0.2 vs 4.1±0.8, Po0.05), supporting the concept of
partial resolution of the renal injury. Plasma creatinine (0.16±
0.01 mg per 100 ml) and blood urea nitrogen (35±3 mg per
100 ml) increased significantly (Po0.05 vs DOCAþAng II),
indicating cessation of hyperfiltration. Relative heart weight
dropped significantly, whereas the resolution of cardiac fibrosis
was not significant (Table 2).
DISCUSSION
Proteinuria and glomerular injury are the final common
pathways in chronic kidney diseases leading to end-stage
renal disease. However, in C57BL/6 mice it is notoriously
difficult to induce glomerular injury and proteinuria.2,4 Rats
are much more sensitive to the effects of Ang II infusion than
mice, and kidney injury is evident in rats within 14 days.7
The replication of renal disease models in mice with the
possibility to employ genetically modified strains would be
very useful in characterizing the specific impacts of defined
genetic traits on the pathophysiological processes involved.2
Mouse models of hypertension are rather disappointing
because of the small extent or even the lack of renal
injury.3,4,8 In contrast, severe renal injury and heavy protein-
uria in the nephrotic range developed in the DOCAþAng II
mice over a short time period.
Why do DOCAþAng II mice develop pronounced
glomerular injury in comparison to isolated DOCA or Ang
II treatment? By titrating blood pressure with increasing
doses of Ang II, we tried to exclude that the injury was simply
due to higher blood pressure in DOCAþAng II mice.
Although indirect methods like tail cuff plethysmography
have limitations in mice, they are suitable for measuring
blood pressure if large blood pressure differences (415 mm
Hg) are found and for discriminating from ‘normotensive’
to ‘hypertensive’ as performed in this study.9,10 Despite
nephrotic range proteinuria, we found no visible damage of
basement membranes and podocytes on electron microscopy.
Interestingly, models with endothelial dysfunction have been
described that can lead to proteinuria without foot process
effacement.11 In vitro data have shown that aldosterone pre-
treatment potentates the response to Ang II by increasing
the number of AT-1 receptors.12 Enhanced expression of the
AT-1 receptor would render the DOCA mice more sensitive
to the deleterious effects of the Ang II infusion. However, we
were unable to detect any upregulation of the AT-1a or AT-2
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Figure 2 | Quantification of gene expression. RT-PCR analyses of mRNA from whole kidney cortex demonstrated increased mRNA expression
of (a) matrix proteins, profibrotic markers and (b) chemokines in DOCAþAng II mice. *Po0.05, **Po0.01, ***Po0.001 vs controls.
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receptor mRNA by RT-PCR. However, it has been described in
vascular smooth muscle cells that aldosterone potentates
signal-transduction effects induced by Ang II through enhan-
cing the activity of mitogen-activated protein kinases.13,14
Thus, aldosterone may enhance the deleterious effects of
Ang II in our model by amplifying postreceptor signal-
transduction pathways. Glomerular hypertrophy is another
important parameter that can lead to glomerular damage.15
Therefore, the trophic effect of DOCA salt on glomerular size
may have rendered the glomeruli in the DOCAþAng II mice
more sensitive to the deleterious effects of Ang II. More than
30 years ago, Hill16 reported that DOCA pretreatment of rats
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Figure 3 | Proteinuria. (a) Pronounced albuminuria was found in the DOCAþAng II mice. Proteinuria was matched by significantly
increased (b) plasma cholesterol levels and (c) proteinaceous cast on PAS-stained kidney sections (original magnification  200).
(d) Semiquantitative analysis of the protein casts by scoring. *Po0.001 vs all other groups.
Table 1 | General parameters
N Body weight (g) SBP (mm Hg) Plasma creatinine (mg per 100 ml) Plasma BUN (mg per 100 ml)
Controls 8 24.5±0.4 92±2 0.13±0.01 35±1
DOCA 9 23.7±0.5 102±1** 0.10±0.01 18±1**
Ang II 11 24.3±0.4 121±1** 0.22±0.01** 50±1**
DOCA+AngII 10 22.2±0.5* 142±1# 0.10±0.02 25±2**
Ang II, angiotensin II; BUN, blood urea nitrogen; DOCA, deoxycorticosterone acetate; SBP, systolic blood pressure.
*Po0.05, **Po0.001 vs controls, #Po0.001 vs all groups.
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rendered the kidney abnormally prone to lesions after high-
pressure injection of saline. Ang II infusion alone induces
renal vasoconstriction as indicated by the reduced renal
function in these mice in this study. Especially, preglomerular
vasoconstriction may at least in part protect the glomerulus
from the barotrauma of systemic hypertension. The combina-
tion of uninephrectomy and DOCA salt application may have
reduced the myogenic autoregulatory capacity of the kidney
and therefore increased the relative glomerular transmission
of the systemic pressure induced by the Ang II infusion.17 The
glomerular injury found in the DOCAþAng II mice was
focal and segmental leaving enough glomeruli intact to
maintain a better renal function in these mice by increased
glomerular pressure and increased single-nephron glomerular
filtration rate despite severe glomerular injury. Although we
cannot finally answer the question why C56/black/6 mice are
resistant to many renal diseases and develop only mild
changes, we would suggest that a high preglomerular resis-
tance may contribute to this phenomenon. C57BL/6 mice
may resemble spontaneously hypertensive rats, in which it is
also believed that a high preglomerular resistances protects
against glomerular injury despite high blood pressure.18
Suitable models of cardiac fibrosis and scarring are
also lacking in C57BL/6 mice. Besides cardiac hypertrophy,
the hearts of the DOCAþAng II mice revealed extensive
fibrosis and hypertrophic transcriptional changes.6 Therefore,
this model may also be of interest to further study the
development of cardiac hypertensive injury in C57BL/6 mice.
Less is known about the process of endogenous repair of
renal structure. The DOCAþAng II mice are suitable models
to study resolution of renal and cardiac injury since complete
removal of the cause of injury is easy to achieve. SBP dropped
and proteinuria decreased within days, although it did not
reach control levels. The glomerular damage dropped but did
not resolve within the observation period of 28 days. Thus,
this model may also be useful to examine genes of interest in
the healing of renal damage.
What is the clinical correlate of the DOCAþAng II mice in
humans? Obviously the combination of hyperaldosteronism
and high renin (resulting in high Ang II levels) is uncommon
in patients. One may speculate over a patient with hyper-
aldosteronism (DOCA pellet) and renovascular hypertension
(resulting in high Ang II levels). However, our model was
not developed to mimic a specific human disease but to study
the pathogenesis of hypertensive glomerular injury and
proteinuria in C7black/6 mice.
In summary, we present a new model of rapidly inducible
hypertensive renal and cardiac injury by combining uni-
nephrectomy and DOCA salt with Ang II infusion in C57BL/6
mice. This model will facilitate the examination of patho-
mechanisms of hypertensive end-organ damage as well as its
repair process in genetically manipulated mice.
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Figure 4 | Systolic blood pressure (SBP). SBP values of the four
groups over the time of the experiment are shown.
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Figure 5 | Cardiac changes. (a) An increased heart weight was found
in the DOCAþAng II mice. Histological examinations revealed
extensive fibrosis and scarring in the DOCAþAng II mice. (b) These
changes were rarely found in ANG II mice (PAS, original magnification
 100). (c) Semiquantitative analysis of the fibrotic lesions. *Po0.001
vs all other groups, #Po0.05 vs controls.
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MATERIALS AND METHODS
Animal procedures
Ten-week-old male C57BL/6N mice (20–25 g; Charles River, Sulzfeld,
Germany) were uninephrectomized under isoflurane 2 weeks before
the start of the experiment. At day 0, the DOCA and the DOCAþAng
II mice received subcutaneous implantation of a 50 mg DOCA pellet
(Innovative Research, Sarasota, FL, USA). The DOCA group was given
drinking water containing 1% NaCl. At day 7, the Ang II and the
DOCAþAng II mice received subcutaneous implantation of an
osmotic mini-pump (Alzet 1002; Charles River) delivering 1.5 ng
Ang II (Sigma, Deisenhofen, Germany) per minute and per gram
body weight for 2 weeks. At day 21, the animals were sacrificed.
The procedures in the different groups are summarized below.
To study the reversibility of the changes, the DOCA pellet and
the mini-pump were removed in another set of animals (n¼ 7) and
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Figure 6 | Quantification of gene expression. RT-PCR analyses of mRNA from the heart ventricles showed that atrial natriuretic protein
(ANP), brain natriuretic protein (BNP), and the ratio of b/a-MHC (myosin heavy chain) were slightly increased in the Ang II mice. A further
increase was found in the DOCAþAng II mice. In addition, increased fibronectin expression was found in these mice. *Po0.05, **Po0.01,
***Po0.001 vs controls.
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Figure 7 | Electron microscopy. Micrographs of a control and a
DOCAþAng II mouse showing an overview (original magnification
 700) and detailed glomerular ultrastructure, including podocytes,
podocyte foot processes, glomerular basement membrane, and
endothelium (original magnification  7000).
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Figure 8 | Glomerular size. An increased glomerular volume
( 106 mm3) was found in the DOCA and DOCAþAng II mice.
*Po0.05, **Po0.025 vs controls.
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Ang II, angiotensin II; DOCA, deoxycorticosterone acetate.
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changes in blood pressure, albuminuria, and renal and cardiac
injury were followed the next 28 days. Approval was obtained from
the University Animal Care Committee.
Blood pressure and albuminuria
SBP was measured using tail cuff plethysmography (TSE Systems,
Bad Homburg, Germany) as previously described.1 Urine collections
were obtained by placing the mice in metabolic cages for 6 h with
access to drinking water. Albuminuria was measured with an
enzyme-linked immunosorbent assay (Bethyl Laboratories, Montgo-
mery, TX, USA). Urinary albumin values were divided by urine
creatinine. Creatinine, blood urea nitrogen, and cholesterol were
measured using an autoanalyzer (Hitachi 717; Roche, Mannheim,
Germany).
Removal of the organs
Animals were sacrificed at week 5. Blood was drawn from the aorta
under isoflurane anesthesia. Kidney and heart were removed. The
ventricular heart weight was measured. Kidney and heart tissue was
fixed in 4% buffered formalin. For RNA analysis, renal cortex and
heart tissue were snap frozen.
Histology
Tissues were stained with PAS reagent. Glomerular injury was
measured by qualitative scoring. The score 0–3.0 indicates no injury,
1 mild injury in less than a quarter of the glomerular tuft, 2 damage
of more than a quarter of the glomerular tuft, and 3 damage of
the whole glomerulus. Planimetric examinations of glomerular
cross-sectional area were performed as described.19 For cardiac
fibrosis, high-power fields of the right and left ventricles were judged
to have no (score¼ 0), light (score¼ 1), moderate (score¼ 2), or
severe fibrosis (score¼ 3). Sections postfixed with 1% osmium
tetroxide and embedded in araldit were observed under electron
microscope. Ultrathin sections were stained and photographed
using a transmission electron microscope (EM 902; Zeiss).
Real-time RT-PCR
Total RNA from kidney cortex or from the ventricles was prepared as
described previously.20 Mouse-specific PCR primers were used. The
presented results are the mean of 3–6 independent RT-PCRs each
performed with RNA pooled from 2–4 mice.
Statistics
All data were tested for normal distribution with the Kolmogorov–
Smirnov test. Variables were expressed as mean±s.e.m. Analysis of
variance with post hoc Scheffe test to correct for multiple compa-
rison or the Kruskal–Wallis test with Dunn’s multiple comparison
were used as appropriate. The reversal data were compared with the
DOCAþAng II data by the Mann–Whitney U-test. Friedman
statistics with Dunn’s multiple comparison test for repeated
measures were calculated to assess changes over time for albumin-
uria after reversal of hypertension. Statistical significance was
defined as Po0.05.
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